ACRS Stock Annual Income Statement. Download in Excel
Aclaris Therapeutics Inc.
ACRS 
NGS
Sector: Healthcare
Industry: Biotechnology
2.72
USD
-0.05
(-1.81%)
Previous close: 2.77 Open: 2.74 Bid: 2.75 Ask: 3.0
52 week range
0.86 5.17
Mkt Cap: 233 M Avg Vol (90 Days): 2,353,484
Last updated: Monday 23rd December 2024
Financials
ACRS Income Statement
Annual
| Invalid date | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | Dec-23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| AccretionOnPreferredStock | 3 M | |||||||||
| Amortization of intangibles | -31000.0 | -75000.0 | 75000.0 | 7 M | 7 M | 75000.0 | 75000.0 | |||
| Basic EPS from continuing operations | -3.9 | -1.2 | -1.6 | -1.33 | -1.27 | |||||
| Basic EPS total | -3.9 | -1.2 | -1.6 | -1.33 | -1.27 | |||||
| Basic weighted shares outstanding | 6 M | 21 M | 28 M | 33 M | 41 M | 43 M | 57 M | 65 M | 70 M | |
| BasicDiscontinuousOperations | -1.16 | |||||||||
| Cost of sales | -1 M | -4 M | 4 M | 5 M | 5 M | 12 M | 18 M | |||
| Depletion | 3 M | |||||||||
| Depreciation | -90000.0 | -120000.0 | -370000.0 | -1 M | 2 M | 1 M | 800000.0 | 700000.0 | 800000.0 | |
| Depreciation unreconciled | 5 M | 3 M | ||||||||
| DepreciationAndAmortization | -90000.0 | -120000.0 | -370000.0 | -1 M | 2 M | 1 M | 800000.0 | 700000.0 | 800000.0 | |
| DevelopmentExpense | 4 M | |||||||||
| Diluted EPS total | -3.79 | -2.25 | -2.44 | -4.03 | -3.9 | -1.2 | -1.6 | -1.33 | -1.27 | |
| Diluted normalized net income/share | -1.6 | -1.33 | -1.27 | |||||||
| Diluted weighted shares outstanding | 5 M | 21 M | 28 M | 21 M | 41 M | 57 M | 65 M | 70 M | ||
| DilutedDiscontinuousOperations | -1.54 | |||||||||
| GainOnSaleOfPPE | 200000.0 | |||||||||
| GainOnSaleOfSecurity | 89000.0 | 152000.0 | 678000.0 | 487000.0 | ||||||
| GainsLossOnDisposalOfDiscontinuedOperations | -552000.0 | 1 M | 139000.0 | |||||||
| GeneralAndAdministrativeExpense | 5 M | 15 M | 19 M | 26 M | 28 M | 21 M | 24 M | 25 M | 32 M | |
| Gross operating profit | 476000.0 | 2 M | 172000.0 | 1 M | 2 M | 18 M | 13 M | |||
| ImpairmentOfCapitalAssets | 19 M | |||||||||
| Income before tax | -21 M | -48 M | -70 M | -82 M | -114 M | -51 M | -91 M | -87 M | -89 M | |
| Income restructuring and M&A | 3 M | 100000.0 | 3 M | |||||||
| Income taxes | -2 M | -182000.0 | -367000.0 | |||||||
| InterestExpenseNonOperating | 87000.0 | 5000.0 | 4 M | |||||||
| MiscOtherSpecialCharges | 104000.0 | 488000.0 | 2 M | 3 M | -2 M | -424000.0 | -1 M | 3 M | 9 M | |
| Net income from total operations | -21 M | -48 M | -69 M | -83 M | -161 M | -51 M | -91 M | -87 M | -88 M | |
| NetIncomeCommonStockholders | -23 M | -48 M | -69 M | -83 M | -114 M | -51 M | -91 M | -87 M | -88 M | |
| NetIncomeContinuousOperations | -21 M | -48 M | -69 M | -83 M | -161 M | -51 M | -91 M | -87 M | -88 M | |
| NetIncomeDiscontinuousOperations | -552000.0 | -63 M | -285000.0 | |||||||
| NetNonOperatingInterestIncomeExpense | -87000.0 | -5000.0 | -4 M | |||||||
| Normalized income | -106 M | |||||||||
| Operating income | -21 M | -49 M | -72 M | -85 M | -111 M | -51 M | -90 M | -90 M | -97 M | |
| Operating income before depreciation (EBITDA) | -20 M | -48 M | -70 M | -80 M | -107 M | -47 M | -64 M | -84 M | -115 M | |
| OperatingExpense | -21 M | -49 M | -73 M | 87 M | 93 M | 50 M | 67 M | 103 M | 129 M | |
| Other income net | -104000.0 | -488000.0 | -2 M | -3 M | 7 M | 3 M | 25 M | -2 M | 27 M | |
| OtherGainLossFromDispositionOfDiscontinuedOperations | 14 M | 424000.0 | ||||||||
| OtherGandA | 5 M | 15 M | 19 M | 26 M | 28 M | 21 M | 24 M | 25 M | 32 M | |
| OtherImpairmentOfCapitalAssets | -289000.0 | -216000.0 | 4 M | 7 M | ||||||
| OtherOperatingExpenses | -21 M | -49 M | -73 M | -139 M | 1000000.0 | 1 M | 1 M | 1 M | 1 M | |
| OtherunderPreferredStockDividend | 3 M | |||||||||
| PreferredStockDividends | 3 M | |||||||||
| PromotionAndAdvertising | 4 M | |||||||||
| RentAndLandingFees | 5 M | 15 M | 19 M | 26 M | ||||||
| Research & development expense | 15 M | 33 M | 40 M | 61 M | 65 M | 29 M | 44 M | 78 M | 98 M | |
| ResearchExpense | 15 M | 33 M | 40 M | 61 M | 65 M | 29 M | 44 M | 78 M | 98 M | |
| RestructringAndMnAIncome | 3 M | 100000.0 | 3 M | |||||||
| Revenue per share | -31000.0 | -75000.0 | 518000.0 | 7 M | 7 M | 75000.0 | 75000.0 | |||
| SalariesAndWages | -891000.0 | -6 M | -14 M | -17 M | ||||||
| Selling Gen & administrative expense | 5 M | 15 M | 33 M | 26 M | 28 M | 21 M | 24 M | 25 M | 32 M | |
| SellingAndMarketingExpense | 14 M | 170000.0 | 5 M | |||||||
| SellingExpense | 14 M | 170000.0 | ||||||||
| Special income/charges | -19 M | -100000.0 | -3 M | |||||||
| Total Income available for interest expense (EBIT) | -21 M | -48 M | -70 M | -82 M | -113 M | -49 M | -65 M | -85 M | -116 M | |
| Total common shares outstanding | 20 M | 26 M | 31 M | 41 M | 42 M | 52 M | 67 M | 71 M | ||
| Total net income | -21 M | -48 M | -69 M | -83 M | -161 M | -51 M | -91 M | -87 M | -88 M | |
| Total ordinary shares | 71 M | 71 M | 71 M | 71 M | 71 M | 71 M | 71 M | 71 M | 71 M | |
| Total revenues | 2 M | 6 M | 4 M | 6 M | 7 M | 30 M | 31 M | |||
| TotalExpenses | -21 M | -49 M | -74 M | 82 M | 97 M | 55 M | 72 M | 115 M | 148 M | |
| TotalRevenue | 2 M | 6 M | 4 M | 6 M | 7 M | 30 M | 31 M | |||
| WriteDown | 5 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS is a complete Excel stock solution
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel
MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.
I like to access historical closing prices on a particular date. That makes tracking performance easy.